Edgewise (EWTX) CBO Derakhshan Behrad Sells Shares, Receives RSUs

What Happened Derakhshan Behrad, Chief Business Officer of Edgewise Therapeutics (EWTX), reported multiple transactions on Aug 12, 2026. He exercised/converted 13,281 derivative shares (5,781 and 7,500) at $0.00 and those same amounts were recorded as disposed (derivative withholding). In open-market activity he sold 5,100 shares in several trades at average prices in the low $40s for aggregate proceeds of approximately $223,424. He was also granted two RSU awards totaling 150,000 RSUs (50,000 and 100,000 RSUs) for no cash consideration.

Key Details

• Transaction date: August 12, 2026; Form filed Aug 14, 2026 (timely within standard Form 4 window).
• Sales: 5,100 shares sold in multiple transactions; average prices reported with ranges from about $43.30 to $44.54; total proceeds ≈ $223,424.
• Exercises/Conversions: 5,781 and 7,500 derivative shares exercised/converted at $0.00 (13,281 total); corresponding disposals of those derivative shares were reported at $0 (derivative withholding).
• Awards: Two RSU grants — 50,000 and 100,000 RSUs (total 150,000) awarded for no additional cash; RSUs vest per the filing’s vesting schedules (see footnotes).
• Tax/timing notes from filing: Some sales were “sell-to-cover” to satisfy statutory tax withholding on RSU vesting (footnote F1). Prices reported for multi-trade sales are averages with ranges provided (footnotes F2–F5).
• Shares owned after transaction: Not specified in the information provided here.

Context

• The filing shows exercises/conversions of derivatives and immediate withholding/disposition of shares and separate open-market sell transactions to cover tax obligations—these are commonly administrative (sell-to-cover) rather than discretionary market-timing sales. Footnotes explain the sell-to-cover nature and give the per-trade price ranges.
• The RSU grants are awards (not purchases) and vest over future periods per the stated schedules; such awards are compensation and do not by themselves signal a bullish purchase by the insider.
• F9 notes a separate option vesting schedule (1/48 monthly beginning Sept 12, 2026) referenced in the filing.